{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T23:33:51Z","timestamp":1789947231208,"version":"4.0.1"},"reference-count":32,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2002,2,20]],"date-time":"2002-02-20T00:00:00Z","timestamp":1014163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2002,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The role of angiogenesis for the progressive growth and metastatic process of tumours is well established. What is not clear, though, is the clinical prognostic significance of the angiogenic factors in malignant haematological diseases. In this study, we have assessed the plasma and serum levels of two major angiogenic factors, vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (b\u2010FGF) in 55 patients affected by chronic myeloproliferative disorders (CMD). This series included 25 patients with essential thrombocythemia (ET), 10 patients with chronic myelocytic leukaemia (CML), 14 patients with polycythemia vera (PV), and 6 patients with primary myelofibrosis (MF), and they were compared to 20 healthy control subjects. In all patients the plasma VEGF concentration was significantly increased to the healthy control group (<jats:italic>P<\/jats:italic> &lt; 0.004). The highest concentrations were found in the patients with ET (178.25 \u00b1 125.22 pg\/ml). The VEGF levels were significantly higher in CMD patients with vascular complications than those in CMD patients without complications (<jats:italic>P<\/jats:italic> &lt; 0.01). The b\u2010FGF serum levels also appeared to be significantly higher in almost all the CMD patients compared to the control group (<jats:italic>P<\/jats:italic> &lt; 0.07). A significant correlation was found between the VEGF levels and the platelet count in the ET patients and the spleen index in the CML patients. VEGF level, in this study, is associated with increased risk of thrombotic complications. There is evidence of increased levels of soluble angiogenic factors in malignant haematological disorders, but their contribution to the progression of diseases is yet unclear. Am. J. Hematol. 69:159\u2013163, 2002. \u00a9 2002 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ajh.10020","type":"journal-article","created":{"date-parts":[[2002,8,25]],"date-time":"2002-08-25T23:10:52Z","timestamp":1030317052000},"page":"159-163","source":"Crossref","is-referenced-by-count":46,"title":["Soluble angiogenic factors: Implications for chronic myeloproliferative disorders"],"prefix":"10.1002","volume":"69","author":[{"given":"C.","family":"Musolino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Calabro'","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Bellomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Martello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Loteta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Pezzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Alonci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,2,20]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64511-7"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.3.765"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64739-6"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.2.94"},{"key":"e_1_2_1_6_2","first-page":"99","article-title":"The diagnostic and prognostic value of tumor angiogenesis","volume":"582","author":"Szabo S","year":"1998","journal-title":"Eur J Surg Suppl"},{"key":"e_1_2_1_7_2","first-page":"203","article-title":"Regulation of angiogenesis via vascular endothelial growth factor receptors","volume":"60","author":"Veikkola T","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.158"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65550-2"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0195-27"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/86.5.356"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(00)00003-4"},{"key":"e_1_2_1_13_2","first-page":"151","article-title":"Vascular endothelial growth factor (VEGF), basic fibroblast growth factor (b\u2010FGF) and soluble interleukin\u20102 receptor (sIL\u20102R) concentrations in peripheral blood as markers of pituitary tumours","volume":"101","author":"Komorowski J","year":"2000","journal-title":"Cytobios"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01547.x"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1997.368"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01752.x"},{"key":"e_1_2_1_17_2","first-page":"800","article-title":"Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood","volume":"85","author":"Di Raimondo F","year":"2000","journal-title":"Hematologica"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.8.3167"},{"key":"e_1_2_1_19_2","first-page":"815","article-title":"Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia","volume":"3","author":"Perez\u2010Atayde AR","year":"1997","journal-title":"Am J Pathol"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.9.3064.409k07_3064_3073"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6690154"},{"key":"e_1_2_1_22_2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1182\/blood.V95.1.309","article-title":"Evidence of increased angiogenesis in patients with acute myeloid leukaemia","volume":"95","author":"Hussong JW","year":"2000","journal-title":"Blood"},{"key":"e_1_2_1_23_2","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1182\/blood.V95.8.2637","article-title":"Increased angiogenesis in the bone marrow of patients with acute leukemia","volume":"95","author":"Padr\u00f4\u00f2 T","year":"2000","journal-title":"Blood"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6693515"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.6.2240"},{"key":"e_1_2_1_26_2","first-page":"1870","article-title":"Vascular Endothelial Growth factor, a possible paracrine growth factor in human acute myeloid leukemia","volume":"89","author":"Fielder W","year":"1998","journal-title":"Blood"},{"key":"e_1_2_1_27_2","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1182\/blood.V94.11.3717","article-title":"Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukaemia","volume":"94","author":"Aguayo A","year":"1999","journal-title":"Blood"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.2.663"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1159\/000012095"},{"key":"e_1_2_1_30_2","first-page":"5687","article-title":"Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation","volume":"55","author":"Katock O","year":"1995","journal-title":"Cancer Res"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.19.7.1757"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.10.3374"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-472X(00)00508-7"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.10020","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.10020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T11:51:51Z","timestamp":1700221911000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.10020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,2,20]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,3]]}},"alternative-id":["10.1002\/ajh.10020"],"URL":"https:\/\/doi.org\/10.1002\/ajh.10020","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,2,20]]}}}